Monday 9th of December the PanACEA General Assembly (GA) met again for its quarterly assembly to report and discuss the progress of the project. The first phase of the BTZ043 trial has started at the end of November at UCTLI and TASK Applied Science. Preparations for the SUDOCU and PHENORIF trials are progressing. Next time,…
The new drug substance BTZ043 is being tested on patients for the first time in a Phase II study performed by the PanACEA consortium. The trial is carried out in Cape Town, South Africa at TASK Applied Science Clinical Research Centre and the University of Cape Town Lung Institute (UCTLI). The study is funded by…
We are pleased to announce that our consortium has added to trials two its portfolio. The SUDOCU and PHENORIF trials replace the Q203 study that was initially planned in the Grant Agreement. The trials will take place in South Africa and Tanzania in 2020. Having established the maximum tolerated dose of rifampicin in the HIGHRIF…
Read more PanACEA adds SUDOCU and PHENORIF trials to portfolio
The PanACEA HIGHRIF trial that started in the first phase of PanACEA has continued in the current programme and has succesfully come to an end. The maximum tolerated dose of rifampicin was identified at 40mg/kg. Martin Boeree recently presented the results at The 50th Union World Conference on Lung Health in Hyderabad, India. The publication…
Ifakara Health Institute
Bagamoyo, Tanzania
PanACEA has enrolled the first patients in the first cohort of the BTZ043 trial. BTZ043 is a new compound with activity against tuberculosis. The trial is a phase Ib/IIa study to assess the safety and tolerability of BTZ043 and to evaluate bactericidal activity of different doses. The trial takes place at the University of Cape…
The quarterly SimpliciTB General Assembly (GA) met by teleconference on the 24th October. Once again there was excellent representation of the collaborating groups with 15 attendees from 7 countries. The Executive Group (EG) have met regularly and gave a report on contractual arrangements, finance, collaborations, and capacity development. There was a further call for membership proposals…
In the quarterly meeting of the General Assembly of PanACEA on 23rd of September an update was given on the progress of the trials and the capacity development plans. The operational teams and study teams are working hard for the final preparations of the BTZ043 trial that will start in November of 2019. This phase…
On Tuesday 10th of September the 12th edition of the International Workshop on Pharmacology of Tuberculosis Drugs took place in London. The annual platform brings together experts to share the latest findings in the field of TB clinical pharmacology. From this perspective, Lindsey te Brake presented the PK findings of the PanACEAII HR1 trial. Elin…
Read more 12th International Workshop on Clinical Pharmacology of Tuberculosis Drugs
The yearly INTERTB symposium, organised by dr. Amina Jindani, was held in London on Monday 9th of September. Martin Boeree presented the results of the PanACEAII HR1 trial and opened the discussion on the optimal dose of rifampicin. Other speakers were, amongst others, consortium members Patrick Phillips, Timothy McHugh and Gerry Davies.
